All articles

Despite Primary Endpoint Falling Short, Sanofi Moving Amlitelimb Forward

Mural Oncology Mulls Strategic Alternatives After Latest Failure With IL-2 Candidate

Pfizer Shelves GLP-1 Obesity Drug After Liver Injury In A Patient

Annexon’s C1q Targeting Of Complement System Could Bring About First Treatment For GBS

Bristol-Myers Squibb Puts Its Hat Into The Ring In Targeting 1st-Line Liver Cancer With OPDIVO-Based Regimen

Opthea Runs Out Of Options With Failed Wet-AMD Studies, Reduces Workforce By 65%

To Get Phase 3 Program Going Tempest Seeks Strategic Alternatives For Amezalpat For Liver Cancer

Bristol-Myers Squibb Nabs FDA Regulatory Wins With OPDIVO And Yervoy Combination For CRC

Scroll to Top